2021-06-23
Characterization of tumor response after administration of rituximab in pediatric B-NHL
2021-06-23 • Maria Bethke, Georg Varga, Toni Weinhage, Harshana Sabharwal, Karin Mellgren, Gerrit Randau, Meike Rolfing, Helmut Wittkowski, Dirk Foell, Ulf Mich...
Background Mature aggressive B-cell lymphoma are heterogenous malignancies that make up more than half of all diagnosed Non-Hodgkin lymphoma in children and adolescents. The overall survival rate increased over the last decades to 80–90%, due to fine tuning of polychemotherapy. However, new therapeutic implications are needed to further increase the overall survival. Current clinical trials analyze the therapeutic effect of rituximab in pediatric patients, while the mechanism of action in vivo is still not fully u…